Synchron — 2026 Pivotal Trial & the First BCI PMA

Fetch status: summary-derived — Medical Design & Outsourcing (the Oxley interview) and Tech Times both returned HTTP 403 to WebFetch; the Clinical Trials Arena COMMAND write-up fetched cleanly and anchors the trial facts. Series D and pivotal-timing figures are triangulated across multiple consistent secondary summaries. Canonical interview URL preserved for refetch.

The headline

Synchron's Stentrode reaches the motor cortex through a blood vessel (endovascular, via the jugular) rather than open-skull surgery. The company is preparing a pivotal clinical trial in 2026 — the study it must clear before it can ask the FDA for the first premarket approval (PMA) of an implantable BCI. If the pivotal study succeeds, Synchron would be the first company positioned to file a PMA on a permanently implanted brain-computer interface.

COMMAND feasibility trial (the foundation; quoted)

• Six patients with severe chronic bilateral upper-limb paralysis unresponsive to prior therapy.
• Primary endpoint met: all six achieved no device-related serious adverse events (death or permanent increased disability) over the 12-month evaluation.
• No serious adverse events related to the brain or vasculature; target motor-cortex coverage achieved in all six patients.
• COMMAND was the first US FDA-approved IDE trial of a permanently implanted BCI (NIH BRAIN Initiative–supported; three US sites; NCT05035823).

Financing & timing

• $200M Series D announced November 6, 2025 — earmarked to fund the pivotal trial and prepare the first-generation device for commercial launch.
• The company has also signalled a next-generation interface with "potentially more applications."

Target population

• Relevant to tens of thousands of Americans living with severe paralysis from ALS, stroke, or spinal cord injury.

Significance

This is the regulatory inflection for the minimally-invasive corner of the field. Where Neuralink and Paradromics race on bandwidth, Synchron races on lowest surgical risk + first to a filing. The strategic question the KB has tracked since April — can minimally-invasive beat invasive to market? — now reduces to the pivotal-trial readout and the PMA filing.